# Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

> **NCT01732861** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 20 (actual)

## Conditions studied

- Leukemia Lymphocytic Chronic B-Cell

## Interventions

- **DRUG:** CC-292
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01732861
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-28
- **Primary completion:** 2019-01-23
- **Final completion:** 2019-01-23
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01732861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01732861, "Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01732861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*